한글목차

세계 세팔렉신 시장은 2024년에 3억 7,514만 달러로 평가되었고, 2030년에는 4억 5,811만 달러에 달할 것으로 예상되며, 예측 기간 동안 4.01%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.

이러한 꾸준한 성장 궤적은 주로 효과적이고 비용 효율적인 항생제 치료에 대한 수요 증가에 기인합니다.

1세대 세팔로스포린인 세팔렉신은 호흡기, 피부, 요로, 뼈 등 광범위한 세균 감염 치료에 광범위하게 처방되고 있습니다. 그람 양성균에 대한 광범위한 효능과 높은 안전성, 그리고 저렴한 가격으로 인해 선진국과 신흥국 시장 모두에서 선호되는 항생제입니다.

시장 확대의 주요 요인은 특히 고령화 사회, 면역력이 저하된 사람들, 수술 후 예방적 항생제 투여가 필요한 수술 환자들 사이에서 세균 감염이 증가하고 있다는 점입니다. 세팔렉신은 1차 선택 약물로서 임상적 신뢰성과 유효성이 입증되어 의료 전문가들 사이에서 신뢰를 받고 있습니다.

그러나 시장은 항균제 내성 증가와 더 넓은 활성 스펙트럼을 가진 차세대 항생제와의 경쟁이라는 역풍에 직면해 있습니다. 이러한 도전에도 불구하고 세팔렉신은 비내성 감염증의 치료제로서 여러 치료 영역의 임상 가이드라인에서 존재감을 드러내고 있습니다.

주요 시장 성장 촉진요인

헬스케어 산업의 성장

주요 시장 이슈

제한된 적응증 및 치료 범위

주요 시장 동향

세균 감염 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19가 세계의 세팔렉신 시장에 미치는 영향

제5장 세계의 세팔렉신 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 판매채널별(직접, 간접)
  • 용도별(요로 감염증, 호흡기 감염증, 중이염, 뼈 감염증, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 세팔렉신 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 세팔렉신 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 세팔렉신 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 세팔렉신 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 세팔렉신 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병(M&A)
• 제품 출시
• 최근 동향

제13장 세계의 세팔렉신 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• Aurobindo Pharma Limited
• Lupin Limited
• Dykes & Dunes Enterprises Pvt. Ltd
• Excel Pharma Chem
• Zhejiang Anglikang Pharmaceutical Co., Ltd.,
• Centrient Pharmaceuticals(Zibo) Co., Ltd
• Hubei widely chemical technology Co., Ltd
• Zhejiang Zhebang Pharmaceutical Co., Ltd
• Akums Drugs and Pharmaceuticals Ltd.
• Xi'an Harmonious Natural Biotechnology Co., Ltd

제16장 전략적 제안

제17장 리서치사에 대해 & 면책사항

영문목차

Global Cephalexin market was valued at USD 375.14 million in 2024 and is projected to reach USD 458.11 million by 2030, expanding at a compound annual growth rate (CAGR) of 4.01% during the forecast period. This steady growth trajectory is primarily driven by rising demand for effective and cost-efficient antibiotic treatments.

Cephalexin, a first-generation cephalosporin, is widely prescribed for the treatment of a broad range of bacterial infections, including those affecting the respiratory tract, skin, urinary tract, and bones. Its broad-spectrum efficacy against Gram-positive bacteria, coupled with a strong safety profile and affordability, has positioned it as a preferred antibiotic in both developed and emerging healthcare markets.

A key factor contributing to market expansion is the increasing incidence of bacterial infections, particularly among aging populations, individuals with compromised immune systems, and patients undergoing surgical procedures that require post-operative antibiotic prophylaxis. Due to its established clinical reliability and effectiveness as a first-line treatment, cephalexin continues to be a trusted choice among healthcare professionals.

However, the market faces headwinds from the growing challenge of antimicrobial resistance and competition from newer-generation antibiotics with broader spectrums of activity. Despite these challenges, cephalexin remains relevant for the treatment of non-resistant infections and maintains its presence in clinical guidelines across multiple therapeutic areas.

Key Market Drivers

Growth of the Healthcare Industry

The expansion of the global healthcare sector serves as a significant catalyst for the cephalexin market. The hospital segment, in particular, is witnessing robust growth. In 2022, hospitals accounted for approximately 40% of the global healthcare market, valued at over USD 3.9 trillion. By 2029, this share is expected to increase to 44%, reaching a market size of USD 5.19 trillion.

As hospitals continue to play a central role in healthcare delivery-fueled by increasing demand and a growing global population-the need for reliable, first-line antibiotics such as cephalexin is expected to rise. Cephalexin's versatility in treating common infections such as respiratory, skin, and urinary tract infections makes it an essential component of both inpatient and outpatient care protocols.

Key Market Challenges

Limited Indications and Therapeutic Range

One of the primary limitations affecting the growth potential of the cephalexin market is its relatively narrow therapeutic scope. As a first-generation cephalosporin, cephalexin demonstrates high efficacy predominantly against Gram-positive bacterial strains, which restricts its use in treating more complex or drug-resistant infections.

Its clinical applications are generally confined to mild-to-moderate conditions such as respiratory, skin, urinary tract, and certain dental infections. Consequently, healthcare providers frequently opt for broader-spectrum or more potent alternatives-such as third- and fourth-generation cephalosporins, fluoroquinolones, or combination therapies-particularly in severe or hospital-acquired infections. This limits cephalexin's utility in high-acuity and specialized care settings, constraining its adoption in advanced clinical environments.

Key Market Trends

Increasing Prevalence of Bacterial Infections

The growing global burden of bacterial infections is a major trend shaping the cephalexin market. Bacterial infections account for an estimated 7.7 million deaths annually-roughly one in eight globally-making them the second leading cause of mortality. Alarmingly, nearly 5 million of these deaths are attributed to antibiotic-resistant strains, underscoring the escalating public health challenge posed by antimicrobial resistance.

Cephalexin continues to be widely used in the treatment of common infections such as respiratory tract infections, skin and soft tissue infections, otitis media, and urinary tract infections. The increasing frequency of such infections-driven by urbanization, climate change, poor hygiene, and increased exposure to bacterial pathogens-has sustained the demand for this well-established antibiotic.

Moreover, heightened susceptibility to both community-acquired and hospital-acquired infections, particularly in densely populated regions and developing countries, has reinforced cephalexin's role in clinical practice. Its proven effectiveness, safety profile, and cost-efficiency make it a dependable first-line option across various healthcare settings.

Key Market Players

• Aurobindo Pharma Limited
• Lupin Limited
• Dykes & Dunes Enterprises Pvt. Ltd
• Excel Pharma Chem
• Zhejiang Anglikang Pharmaceutical Co., Ltd.,
• Centrient Pharmaceuticals (Zibo) Co., Ltd
• Hubei widely chemical technology Co., Ltd
• Zhejiang Zhebang Pharmaceutical Co., Ltd
• Akums Drugs and Pharmaceuticals Ltd.
• Xi'an Harmonious Natural Biotechnology Co., Ltd

Report Scope

In this report, the Global Cephalexin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cephalexin Market, By Sales Channel:

• Direct
• Indirect

Cephalexin Market, By End Use:

• Urinary Tract Infection
• Respiratory Infection
• Otitis Media
• Bone Infection
• Others

Cephalexin Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cephalexin Market.

Available Customizations:

Global Cephalexin Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Cephalexin Market

5. Global Cephalexin Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Sales Channel (Direct, Indirect)
  • 5.2.2. By End Use (Urinary Tract Infection, Respiratory Infection, Otitis Media, Bone Infection, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Cephalexin Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Sales Channel
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Cephalexin Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Sales Channel
      • 6.3.1.2.2. By End Use
  • 6.3.2. Mexico Cephalexin Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Sales Channel
      • 6.3.2.2.2. By End Use
  • 6.3.3. Canada Cephalexin Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Sales Channel
      • 6.3.3.2.2. By End Use

7. Europe Cephalexin Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Sales Channel
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Cephalexin Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Sales Channel
      • 7.3.1.2.2. By End Use
  • 7.3.2. Germany Cephalexin Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Sales Channel
      • 7.3.2.2.2. By End Use
  • 7.3.3. United Kingdom Cephalexin Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Sales Channel
      • 7.3.3.2.2. By End Use
  • 7.3.4. Italy Cephalexin Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Sales Channel
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Cephalexin Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Sales Channel
      • 7.3.5.2.2. By End Use

8. Asia Pacific Cephalexin Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Sales Channel
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Cephalexin Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Sales Channel
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Cephalexin Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Sales Channel
      • 8.3.2.2.2. By End Use
  • 8.3.3. South Korea Cephalexin Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Sales Channel
      • 8.3.3.2.2. By End Use
  • 8.3.4. Japan Cephalexin Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Sales Channel
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Cephalexin Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Sales Channel
      • 8.3.5.2.2. By End Use

9. South America Cephalexin Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Sales Channel
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Cephalexin Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Sales Channel
      • 9.3.1.2.2. By End Use
  • 9.3.2. Argentina Cephalexin Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Sales Channel
      • 9.3.2.2.2. By End Use
  • 9.3.3. Colombia Cephalexin Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Sales Channel
      • 9.3.3.2.2. By End Use

10. Middle East and Africa Cephalexin Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Sales Channel
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Cephalexin Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Sales Channel
      • 10.3.1.2.2. By End Use
  • 10.3.2. Saudi Arabia Cephalexin Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Sales Channel
      • 10.3.2.2.2. By End Use
  • 10.3.3. UAE Cephalexin Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Sales Channel
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Cephalexin Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Aurobindo Pharma Limited
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Lupin Limited
• 15.3. Dykes & Dunes Enterprises Pvt. Ltd
• 15.4. Excel Pharma Chem
• 15.5. Zhejiang Anglikang Pharmaceutical Co., Ltd.,
• 15.6. Centrient Pharmaceuticals (Zibo) Co., Ltd
• 15.7. Hubei widely chemical technology Co., Ltd
• 15.8. Zhejiang Zhebang Pharmaceutical Co., Ltd
• 15.9. Akums Drugs and Pharmaceuticals Ltd.
• 15.10. Xi'an Harmonious Natural Biotechnology Co., Ltd

16. Strategic Recommendations

17. About Us & Disclaimer